USANA Health Sciences, Inc. — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended April 4, 2015, compared with the quarter ended March 29, 2014; it does not report 2014 Q1 as the current period. Financial amounts below are in U.S. dollars unless noted.
Business context and reporting period
USANA develops and manufactures nutritional and personal care products sold internationally through independent distributors and preferred customers. It reports one operating segment, with sales across the Americas and Europe and Asia Pacific. At quarter-end, it had approximately 376,000 active Associates and 86,000 active Preferred Customers. Associates generated approximately 92% of product sales; 83.5% of sales were outside the United States.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Net sales | $219.4 million | $182.4 million |
| Gross profit / gross margin | $181.0 million / 82.5% | $148.6 million / 81.5% |
| Operating earnings / operating margin | $29.8 million / 13.6% | $25.1 million / 13.8% |
| Net earnings / net margin | $19.7 million / 9.0% | $16.5 million / 9.1% |
| Diluted EPS | $1.50 | $1.15 |
| Operating cash flow | $23.6 million | $2.5 million |
Cash and cash equivalents were $128.6 million at April 4, 2015, up from $111.1 million at January 3, 2015. Current assets were $211.5 million and current liabilities $110.4 million, yielding working capital of approximately $101.1 million. The current ratio was approximately 1.9. No borrowings were outstanding under the $75 million credit facility; normal-course bank guarantees reduced available borrowing capacity by $4.4 million. The company reported compliance with its credit covenants.
Investing cash outflow was $7.4 million, including $5.8 million of property and equipment purchases. Financing cash inflow was $0.9 million. Inventory increased to $51.0 million from $45.2 million at year-end.
Material changes versus the prior comparable period
- Sales increased 20.3% year over year. Asia Pacific sales rose 31.4%, led by Greater China, where sales increased 43.0%; China sales were $83.8 million versus $38.8 million.
- Foreign exchange reduced reported sales by approximately $9.2 million. Excluding currency effects, sales increased 25.3%.
- Net earnings increased 19.0%; diluted EPS rose 30.4%, supported in part by a 9.1% decrease in diluted weighted-average shares. The filing attributes $0.13 of diluted EPS to share repurchases over the prior twelve months.
- Gross margin improved by 100 basis points. Associate incentives rose to 46.2% of sales from 43.2%, offsetting some gross-margin and SG&A leverage benefits. SG&A declined to 22.7% of sales from 24.4%.
- Operating cash flow increased substantially year over year, reflecting higher earnings and timing-related changes in liabilities and other items; inventory growth partly offset the improvement.
Outlook, commentary, risks and unusual items
- Management expected Associate incentives to range from 44.0% to 44.5% of sales for the remainder of 2015. This is the principal quantified expense outlook; no formal full-year revenue or earnings guidance is provided in the supplied filing.
- Management expected the new China manufacturing facility to become operational in early 2016. The anticipated investment was $40 million; $20.8 million had been incurred through Q1 2015, including $2.0 million during the quarter.
- USANA planned to begin operations in Indonesia later in 2015. Management stated cash, operating cash flow, and the credit facility should meet ordinary-course needs for the foreseeable future, while noting adverse conditions or unusual capital needs could require financing.
- China sales benefited from incentives carried over from late 2014, sales ahead of announced price adjustments, and a more favorable operating environment. Management estimated price-adjustment-related incremental sales at approximately $12 million for the quarter. These factors may affect the comparability and sustainability of growth.
- Currency movements, distributor recruitment and retention, network-marketing dependence, regulation, competition, supplier and shipping disruptions, and higher incentive costs were identified as risks. Port congestion and dockworker strikes increased international shipment lead times and contributed to inventory needs.
- A shareholder derivative suit concerning 2014 equity awards was dismissed without prejudice in March 2015; plaintiffs filed a notice of appeal in April but had not filed the appeal as of the report date. Management said no legal contingency was probable and estimable and viewed a material adverse outcome as unlikely.
Important facts for investors to verify
- Confirm the period: the filing covers Q1 2015, despite the request metadata specifying 2014 Q1.
- Assess whether China’s exceptional growth and the approximately $12 million of price-adjustment-related sales reflect durable customer demand or timing and incentive effects.
- Monitor foreign-exchange impacts, especially given the high proportion of international sales and the $9.2 million reported-sales headwind.
- Track Associate incentive expense against management’s 44.0%–44.5% remainder-of-year expectation and its effect on margins.
- Verify China facility spending, completion timing, and funding needs; also monitor covenant compliance and the credit facility’s April 2016 maturity.
- Follow the derivative lawsuit appeal and any changes in the company’s assessment of legal contingencies.